ArchiMed completed its investment in Deallus in November 2015. Deallus is a global consultancy firm specializing in life sciences; the firm leverages its deep marketing understanding in life sciences and the pharmaceutical industry to partner with clients and help them develop winning strategies.
Deallus was founded in 2004 and works with 25 of the world’s top 30 pharmaceutical, biotechnology and vaccines companies, as well as a wide range of small and medium size life sciences companies, by harnessing objective external perspectives with in-depth market knowledge and rigorous analytical capability. Today Deallus has an established footprint in the US, Europe and Asian markets with offices in London, New York, Princeton, Los Angeles and Tokyo. ArchiMed supported the incumbent management team and executive shareholders in a buyout of the group which was financed 100% through equity in order to allow the company to continue with its organic growth strategy, principally the opening of new offices to provide integrated bespoke solutions to its customers in an increasingly regulated environment.
2004 → Deallus founded
2010 → First US office opened in New York
2015 → Tokyo office opened